Billing Code CGM/95251

This episode reviews the differential diagnosis of paroxysmal adrenergic symptoms, contrasting sympathoadrenal hyperreactivity with catecholamine-secreting neuroendocrine tumors. We analyze the diagnostic utility and pre-test confounding factors of plasma versus fractionated urinary metanephrines, evaluate concurrent features of thyrotoxicosis, carcinoid syndrome, and mast cell activation, and outline evidence-based alpha-blockade protocols prior to surgical or medical intervention.

This episode evaluates postural orthostatic tachycardia syndrome, exploring neuroendocrine and autonomic dysregulation, including hyperadrenergic phenotypes and volume depletion. We examine diagnostic tilt-table criteria, the crucial exclusion of primary endocrine mimics such as pheochromocytoma and adrenal insufficiency, and evidence-based management strategies spanning fludrocortisone, nonselective beta-blockers, alpha-1 agonists, and structured physical reconditioning.

This episode examines subclinical hyperthyroidism, characterized by suppressed serum TSH alongside normal free thyroxine and triiodothyronine. We analyze etiology differentiation between autonomous nodular disease and Graves disease, risk stratification for atrial fibrillation and accelerated bone loss, and guideline thresholds for initiating antithyroid pharmacotherapy or definitive ablation in older adults and postmenopausal patients.

Pretest probability dictates the entire diagnostic workflow for Cushing syndrome by guiding appropriate patient selection for screening and preventing false positives from incidentalomas or physiological hypercortisolism. Because diagnostic tests carry distinct false-positive rates when applied to low-risk populations, initial biochemical evaluation must be strictly reserved for patients with recognizable clinical stigmata or progressive multisystem manifestations. Quantifying clinical probability prevents the diagnostic cascade of unindicated testing, ensuring that abnormal screening results reflect true autonomous cortisol excess rather than benign physiological mimics or stress-induced alterations.

Screening for primary aldosteronism requires measuring the aldosterone-to-renin ratio under standardized conditions, accounting for interfering antihypertensives and hypokalemia. Diagnosis hinges on non-suppressible autonomous aldosterone secretion via confirmatory suppression testing. Once confirmed, adrenal protocol cross-sectional imaging and adrenal vein sampling are essential to reliably differentiate unilateral surgically curable adenomas from bilateral idiopathic adrenal hyperplasia prior to targeted intervention.

Familial partial lipodystrophy mutations causing progressive subcutaneous fat loss from the extremities and trunk with paradoxical fat accumulation in the face and neck. This redistribution precipitates severe insulin resistance, hypertriglyceridemia, and premature cardiovascular disease. Diagnosis relies on physical examination recognizing characteristic fat loss patterns, genetic testing, and metabolic profiling. Management focuses on aggressive metabolic optimization, lifestyle modification, and targeted therapies for dyslipidemia and glycemic control to mitigate long-term cardiovascular and hepatic sequelae.

Emil Theodor Kocher revolutionized endocrine surgery by developing meticulous, sterile, and bloodless thyroidectomy techniques. His standardized operative methods reduced surgical mortality from nearly forty percent to under one percent. Kocher's precise documentation of cachexia strumipriva fundamentally delineated thyroid physiological function and postoperative myxedema, establishing the foundations of modern surgical endocrinology and safe neck exploration.

Calcitonin, secreted by thyroid parafollicular C cells, acts as a physiological antagonist to parathyroid hormone by suppressing osteoclastic bone resorption and renal tubular calcium reabsorption. While minor in routine adult calcium homeostasis, serum calcitonin serves as an indispensable diagnostic and post-thyroidectomy surveillance biomarker for medullary thyroid carcinoma, directly correlating with tumor burden, staging, and systemic progression.

Multiple endocrine neoplasia type 1 arises from inactivating MEN1 tumor suppressor mutations, causing loss of menin function. Clinical manifestations classically feature primary hyperparathyroidism due to multiglandular hyperplasia, enteropancreatic neuroendocrine tumors, and anterior pituitary adenomas. Management prioritizes subtotal parathyroidectomy with transcervical thymectomy, specialized biochemical surveillance, and aggressive multi-phase imaging to detect malignant functional pancreatic lesions early.

This episode evaluates crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, for classic congenital adrenal hyperplasia. By blocking pituitary ACTH secretion independently of glucocorticoid feedback, crinecerfont reduces adrenal androgen excess, including androstenedione. This mechanism permits significant supraphysiologic glucocorticoid dose reduction toward physiologic replacement levels, mitigating long-term iatrogenic metabolic and skeletal complications while preserving adrenal control.